risedronate sodium

ApprovedSmall molecule

risedronate sodium is one of 174 small molecule programs targeting Postmenopausal Osteoporosis. It is currently in Approved.

Indications

Total Trials

Active Trials

173

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postmenopausal OsteoporosisActive, not recruiting

Weight LossActive, not recruiting

Osteogenesis ImperfectaActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

OsteoporosisActive, not recruiting

Postmenopausal OsteoporosisApproved

Active, not recruiting

Weight LossApproved

Active, not recruiting

Osteogenesis ImperfectaPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

OsteoporosisApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

risedronate sodium

Sanofi

Approved

3 2

Trodelvy

Gilead

Preclinical

37 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Tianeptine

Pfizer

Preclinical

1 9

QBX258

Novartis

Preclinical

1 10

Sandostatin

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00054418·216 enrolled

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00082277·237 enrolled

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00354302·497 enrolled

Osteogenesis Imperfecta2 trials

Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?

Completed·SSheffield Children's NHS Foundation Trust·Phase 2·NCT03208582·13 enrolled

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

Completed·WWarner Chilcott·Phase 3·NCT00106028·143 enrolled

Satisfaction2 trials

POWER Point of Care Effect on Satisfaction of Treatment

Completed· Sanofi logo

Sanofi·Phase 4·NCT00549068·2,433 enrolled

Satisfaction and Compliance of Risedronate in PMO

Completed· Sanofi logo

Sanofi·Phase 4·NCT00549965·202 enrolled

Osteoporosis2 trials

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Completed· Sanofi logo

Sanofi·Phase 4·NCT00632216·464 enrolled

Risedronate Sodium in Post Menopausal Osteoporosis

Completed· Sanofi logo

Sanofi·Phase 4·NCT00453492·246 enrolled

Postmenopausal Women1 trial

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

Completed· Sanofi logo

Sanofi·Phase 4·NCT00130403·290 enrolled

5 more indications

Ductal Carcinoma in Situ1 trial

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS

Withdrawn·EETOP IBCSG Partners Foundation·Phase 3·NCT00324714

Fracture1 trial

SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.

Completed· Sanofi logo

Sanofi·Phase 4·NCT00460733·141 enrolled

Prostate Cancer1 trial

Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00043069·71 enrolled

Weight loss1 trial

Weight Loss With Risedronate for Bone Health

Completed·WWake Forest University Health Sciences·Phase 4·NCT03411902·24 enrolled

Postmenopausal Osteoporosis1 trial

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Completed·DDong-A ST Co., Ltd.·Phase 4·NCT05630768·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for risedronate sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — risedronate sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for risedronate sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

risedronate sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Osteogenesis Imperfecta2 trials

Satisfaction2 trials

Osteoporosis2 trials

Postmenopausal Women1 trial

Ductal Carcinoma in Situ1 trial

Fracture1 trial

Prostate Cancer1 trial

Weight loss1 trial

Postmenopausal Osteoporosis1 trial

References

Drug Info

Quick Facts

Related News